Definitive Contract VA26115C0109
Award Date
8/27/15
Potential Completion Date
3/31/16
Potential Value
$86K
Federal Agency
Veterans Integrated Service Network 21
Awardee
Pharmaron, Inc.
Ultimate Awardee
Not listed
NAICS Category
112990 - All Other Animal Production
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Louisville, KY 40202, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is to Pharmaron, Inc., a global contract research organization (CRO) that provides preclinical research services for pharmaceutical and biotechnology companies, as well as government agencies. The contract, valued at $24,900, is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH). The award does not have a set-aside designation.
Pharmaron, which is classified as a...
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. for $24,624.00. The contract is to obtain pharmacokinetic exposure data from mouse PK studies and plasma protein binding assays, which are common preclinical services provided by Pharmaron, a global contract research organization (CRO) specializing in drug discovery and development. This...
This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational...
This firm fixed-price purchase order, valued at $78,300.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Pharmaron, Inc., a minority-owned, for-profit organization classified as a Subcontinent Asian (Asian-Indian) American owned business. The contract is for the testing of compounds to block cardiac ion channels, with a period of performance ending on November 16, 2022. Pharmaron, a global contract research organization (CRO)...
This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Pharmaron, Inc. for $149,520.00. The award is under the NIH Bioanalysis Testing Services 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract vehicle. Pharmaron, a minority-owned, for-profit contract research organization (CRO), will provide pharmacokinetics assessments, toxicity studies, and ion channel testing...
This is a federal contract award to Pharmaron, Inc., a global contract research organization (CRO) specializing in preclinical research services for the pharmaceutical and biotechnology industries, as well as government agencies. The contract was awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), and is part of the NIH Bioanalysis Testing Services 2015-2020 master indefinite-delivery, indefinite-quantity (IDIQ) contract. The...
This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services.
The contract is for testing 20 small molecule compounds in rat pharmacokinetic...
This is a $78,300.00 firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Pharmaron, Inc., a minority-owned for-profit organization. The contract is for testing compounds for the blockage of cardiac ion channels, which is a critical step in the drug development process. As a global contract research organization (CRO), Pharmaron has extensive expertise in preclinical research services, including...
This firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health within the Department of Health and Human Services, to Pharmaron, Inc. for $64,090. The contract is for Pharmaron to conduct a 14-day dose range-finding toxicity study in male and female rats to determine the maximally tolerated dose of an investigational molecule under development by NCATS. Specifically, Pharmaron will test the...
This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The contract is valued at $24,320.00 and does not have a set-aside designation.
The contract is for pharmacokinetic studies of two compounds in non-naive cynomolgus monkeys, using both oral and intravenous routes of administration, with bioanalyses in plasma conducted in triplicate....